Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?

被引：8
|
作者：
Yao, Liqin [1 ]
Jia, Gang [2 ]
Lu, Lingeng [3 ,4 ,5 ]
Ma, Wenxue [6 ]
机构：
[1] Huzhou Univ, Affiliated Hosp 1, Sch Med, Dept Breast & Thyroid Surg, Huzhou 313000, Peoples R China
[2] Peoples Hosp Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Med Oncol, Zhengzhou 450003, Peoples R China
[3] Yale Sch Publ Hlth, Sch Med, Dept Chron Dis Epidemiol, New Haven, CT 06520 USA
[4] Yale Univ, Yale Canc Ctr, 60 Coll St, New Haven, CT 06520 USA
[5] Yale Univ, Ctr Biomed Data Sci, 60 Coll St, New Haven, CT 06520 USA
[6] Univ Calif San Diego, Sanford Stem Cell Clin Ctr, Moores Canc Ctr, Dept Med, La Jolla, CA 92093 USA
来源：
CURRENT ONCOLOGY | 2022年 / 29卷 / 07期
关键词：
breast cancer; cytotoxic T lymphocytes (CTLs); Human Leukocyte Antigen-DR (HLA-DR); neoadjuvant chemotherapy (NACT); pathologic complete response (pCR); tumor-infiltrating lymphocytes (TILs); RECURRENCE SCORE; HLA-DR; EXPRESSION; LYMPHOCYTES; MACROPHAGES; ACTIVATION; WOMEN;
D O I：
10.3390/curroncol29070389
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Neoadjuvant chemotherapy (NACT) was developed with the aims of shrinking tumors or stopping cancer cells from spreading before surgery. Unfortunately, not all breast cancer patients will benefit from NACT, and thus, patients must weigh the risks and benefits of treatment prior to the initiation of therapy. Currently, the data for predicting the efficacy of NACT is limited. Molecular testing, such as Oncotype DX, MammaPrint, and Curebest 95GC, have been developed to assist which breast cancer patients will benefit from the treatment. Patients with an increased level of Human Leukocyte Antigen-DR isotype, tumor-infiltrating lymphocytes, Fizzy-related protein homolog, and a decreased level of tumor-associated macrophages appear to benefit most from NACT.
引用
收藏
页码：4902 / 4913
页数：12
相关论文
共 50 条
  • [1] Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
    Takei, Hiroyuki
    Kurosumi, Masafumi
    Yoshida, Takashi
    Hayashi, Yuji
    Higuchi, Toru
    Uchida, Sayaka
    Ninomiya, Jun
    Oba, Hanako
    Inoue, Kenichi
    Nagai, Shigenori
    Tabei, Toshio
    BREAST CANCER, 2011, 18 (02) : 85 - 91
  • [2] Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
    Hiroyuki Takei
    Masafumi Kurosumi
    Takashi Yoshida
    Yuji Hayashi
    Toru Higuchi
    Sayaka Uchida
    Jun Ninomiya
    Hanako Oba
    Kenichi Inoue
    Shigenori Nagai
    Toshio Tabei
    Breast Cancer, 2011, 18 : 85 - 91
  • [3] THE BREAST 74 (2024) 103635 PREDICTSELECT e IDENTIFYING BREAST CANCER PATIENTS WHO WOULD BENEFIT FROM ENDOPREDICT TESTING
    Ho, K. A.
    Elder, E.
    Elhindi, J.
    Ngui, N.
    Kabir, M.
    Pathmanathan, N.
    BREAST, 2024, 74
  • [4] Do all patients with breast cancer benefit from neoadjuvant chemotherapy?
    Lee, Kyoung Eun
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (06): : 1336 - 1337
  • [5] Neoadjuvant nab-paclitaxel in breast cancer: who stands to benefit?
    Biganzoli, Laura
    McCartney, Amelia
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [6] Endoscopic ultrasound predicts patients with oesophageal cancer who benefit from neoadjuvant therapy
    Balaji, N. S.
    Melhado, R.
    Fowler, A.
    Wariach, N.
    Goddard, A.
    Leeder, P. C.
    Cole, A.
    Iftikhar, S.
    GUT, 2008, 57 : A53 - A53
  • [7] Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy
    Glueck, Stefan
    de Snoo, Femke
    Peeters, Justine
    Stork-Sloots, Lisette
    Somlo, George
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 759 - 767
  • [8] Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy
    Stefan Glück
    Femke de Snoo
    Justine Peeters
    Lisette Stork-Sloots
    George Somlo
    Breast Cancer Research and Treatment, 2013, 139 : 759 - 767
  • [9] Who would benefit from the independence of Quebec?
    Ramadan, NHN
    CANADIAN JOURNAL OF POLITICAL SCIENCE-REVUE CANADIENNE DE SCIENCE POLITIQUE, 2002, 35 (01): : 181 - 182
  • [10] Can Endometrial Cytology Identify Patients Who Would Benefit from Immunotherapy?
    Yanazume, Shintaro
    Kirita, Yukari
    Kobayashi, Yusuke
    Kitazono, Ikumi
    Akahane, Toshiaki
    Mizuno, Mika
    Togami, Shinichi
    Tanimoto, Akihide
    Kobayashi, Hiroaki
    ACTA CYTOLOGICA, 2024, 68 (02) : 128 - 136
12345